Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 IN DEXTROSE 5 IN PLASTIC CONTAINER versus HEPATASOL 8.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 IN DEXTROSE 5 IN PLASTIC CONTAINER versus HEPATASOL 8.
AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER vs HEPATASOL 8%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and nitrogen balance; dextrose provides caloric energy via glycolysis and oxidative phosphorylation.
HEPATASOL 8% (amino acid injection) provides essential and non-essential amino acids to support protein synthesis and correct nitrogen balance in hepatic encephalopathy. It reduces plasma ammonia levels by promoting urea cycle activity and decreasing aromatic amino acids.
Intravenous infusion: 1-1.5 g amino acids/kg/day (equivalent to 28-43 mL/kg/day of Aminosyn II 3.5% in D5W). Rate: infuse via central line at ≤100 mL/hour; peripheral line at ≤125 mL/hour. Adjust based on nitrogen balance and metabolic response.
Intravenous infusion of 500 mL (40 g amino acids) over 3-4 hours, administered once daily or as directed by clinical response.
None Documented
None Documented
Not applicable as a mixture; individual components have varying half-lives. Dextrose: rapid distribution, half-life <1 hour. Amino acids: half-life of infused amino acids is short (minutes) due to metabolism.
Approximately 30-60 minutes for individual amino acids; clinical context: rapid clearance supports continuous infusion to maintain plasma levels.
Aminosyn II 3.5% in Dextrose 5% contains amino acids and dextrose. Amino acids are metabolized; negligible renal excretion of intact amino acids. Dextrose is metabolized. No biliary/fecal elimination of intact drug.
Renal: >95% of administered amino acids are reabsorbed and metabolized; negligible unchanged excretion. Biliary/fecal: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution